Schizophrenia is a leading cause of global disease burden. Current drug treatments are
associated with significant side-effects and have limited efficacy for many patients; …

Clozapine is the only approved antipsychotic for treatment-resistant schizophrenia (TRS).
Although a large body of evidence supports its efficacy and favorable risk-benefit ratio in …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Although antipsychotics have been available for almost 70 years and greatly improved
outcomes for individuals with schizophrenia, all currently available options derive their …

Introduction Schizophrenia is a condition that places a significant burden on individuals with
the condition, their family, and society. A large proportion of those treated for schizophrenia …

The reproducibility of machine-learning analyses in computational psychiatry is a growing
concern. In a multimodal neuropsychiatric dataset of antipsychotic-naïve, first-episode …

Clozapine is the gold standard for treating treatment-resistant schizophrenia although
continuously underutilized. Previous surveys of clinicians have found that some of the most …

Background Although clozapine is effective for treatment-resistant schizophrenia (TRS), the
rate of clozapine prescription is still low. Whereas antipsychotic monotherapy is …

Background Gender disparities in treatment are apparent across many areas of healthcare.
There has been little research into whether clozapine prescription, the first-line treatment for …

Background Clozapine is the only drug licensed for treatment-resistant schizophrenia (TRS)
but the real-world clinical and cost-effectiveness of community initiation of clozapine is …